Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
2 Beaten-Down Dividend Stocks to Buy and Hold was originally published by The Motley Fool Despite soft inflation print, bond ...
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
2don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...
The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the ...
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback